Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice

Vaccine

Volumn 28, Issue 38, 2010, Pages 6374-6381

  Rusakiewicz, Sylvie ^b,c   Dosset, Magalie ^b   Mollier, Karine ^a   Souque, Philippe ^a   Charneau, Pierre ^a   Wain Hobson, Simon ^a   Langlade Demoyen, Pierre ^a   Adotévi, Olivier ^a,b  

^a INSTITUT PASTEUR   (France)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

CD8 T cells; HTERT; Lentiviral vector

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; GAMMA INTERFERON; HLA B ANTIGEN; HLA B7 ANTIGEN; LENTIVIRUS VECTOR; PLASMID DNA; RECOMBINANT LENTIVIRAL VECTOR; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG POTENCY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CANCER VACCINES; CELL LINE; FEMALE; GENETIC VECTORS; HLA-B ANTIGENS; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; LENTIVIRUS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 77955664908     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.071     Document Type: Article

References (39)

1. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999, 10(3):281-287.
2. Romero P., Pittet M., Dutoit V., Zippelius A., Lienard D., Lejeune F., et al. Therapeutic cancer vaccines based on molecularly defined human tumor antigens. Vaccine 2002, 20(Suppl. December (4)):A2-7.
3. Jager E., Ringhoffer M., Karbach J., Arand M., Oesch F., Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996, 66(May (4)):470-476.
4. Schmollinger J.C., Vonderheide R.H., Hoar K.M., Maecker B., Schultze J.L., Hodi F.S., et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci USA 2003, 100(March (6)):3398-3403.
5. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266(December (5193)):2011-2015.
6. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33(5):787-791.
7. Artandi S.E., DePinho R.A. Telomeres and telomerase in cancer. Carcinogenesis 2010, 31(January (1)):9-18.
8. Blackburn E.H. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 2005, 579(February (4)):859-862.
9. Bernhardt S.L., Gjertsen M.K., Trachsel S., Moller M., Eriksen J.A., Meo M., et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006, 95(December (11)):1474-1482.
10. Bolonaki I., Kotsakis A., Papadimitraki E., Aggouraki D., Konsolakis G., Vagia A., et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007, 25(July (19)):2727-2734.
11. Domchek S.M., Recio A., Mick R., Clark C.E., Carpenter E.L., Fox K.R., et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 2007, 67(November (21)):10546-10555.
12. Beatty G.L., Vonderheide R.H. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines 2008, 7(September (7)):881-887.
13. Cortez-Gonzalez X., Zanetti M. Telomerase immunity from bench to bedside: round one. J Transl Med 2007, 5:12.
14. Voskens C.J., Strome S.E., Sewell D.A. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome. Curr Mol Med 2009, 9(August (6)):683-693.
15. Harley C.B. Telomerase and cancer therapeutics. Nat Rev Cancer 2008, 8(3):167-179.
16. He Y., Munn D., Falo L.D. Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert Rev Vaccines 2007, 6(December (6)):913-924.
17. Breckpot K., Aerts J.L., Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 2007, 14(June (11)):847-862.
18. Firat H., Zennou V., Garcia-Pons F., Ginhoux F., Cochet M., Danos O., et al. Use of a lentiviral flap vector for induction of CTL immunity against melanoma, Perspectives for immunotherapy. J Gene Med 2002, 4(January-February (1)):38-45.
19. Rohrlich P.S., Cardinaud S., Lule J., Montero-Julian F.A., Prodhomme V., Firat H., et al. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells. Hum Immunol 2004, 65(May (5)):514-522.
20. Iglesias M.C., Mollier K., Beignon A.S., Souque P., Adotevi O., Lemonnier F., et al. Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol Ther 2007, 15(6):1203-1210.
21. Rohrlich P.S., Cardinaud S., Firat H., Lamari M., Briand P., Escriou N., et al. HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. Int Immunol 2003, 15(June (6)):765-772.
22. Adotevi O., Mollier K., Neuveut C., Cardinaud S., Boulanger E., Mignen B., et al. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin Cancer Res 2006, 12(May (10)):3158-3167.
23. Cortez-Gonzalez X., Sidney J., Adotevi O., Sette A., Millard F., Lemonnier F., et al. Immunogenic HLA-B7-restricted peptides of hTRT. Int Immunol 2006, 18(12):1707-1718.
24. Snyder J.T., Alexander-Miller M.A., Berzofskyl J.A., Belyakov I.M. Molecular mechanisms and biological significance of CTL avidity. Curr HIV Res 2003, 1(July (3)):287-294.
25. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002, 2(April (4)):251-262.
26. Palmowski M.J., Lopes L., Ikeda Y., Salio M., Cerundolo V., Collins M.K. Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 2004, 172(February (3)):1582-1587.
27. Chapatte L., Colombetti S., Cerottini J.C., Levy F. Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors. Cancer Res 2006, 66(January (2)):1155-1160.
28. Adotevi O., Mollier K., Neuveut C., Dosset M., Ravel P., Fridman W.H., et al. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood 2010, 115(April (15)):3025-3032.
29. Lacey S.F., Villacres M.C., La Rosa C., Wang Z., Longmate J., Martinez J., et al. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 2003, 64(April (4)):440-452.
30. Esslinger C., Chapatte L., Finke D., Miconnet I., Guillaume P., Levy F., et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003, 111(June (11)):1673-1681.
31. Dullaers M., Van Meirvenne S., Heirman C., Straetman L., Bonehill A., Aerts J.L., et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 2006, 13(April (7)):630-640.
32. He Y., Zhang J., Mi Z., Robbins P., Falo L.D. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 2005, 174(March (6)):3808-3817.
33. He Y., Zhang J., Donahue C., Falo L.D. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006, 24(May (5)):643-656.
34. Rice J., Ottensmeier C.H., Stevenson F.K. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008, 8(February (2)):108-120.
35. Colombetti S., Levy F., Chapatte L. IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector. Blood 2009, 113(June (26)):6629-6637.
36. Lopes L., Dewannieux M., Gileadi U., Bailey R., Ikeda Y., Whittaker C., et al. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol 2008, 82(January (1)):86-95.
37. Breckpot K., Emeagi P., Dullaers M., Michiels A., Heirman C., Thielemans K. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum Gene Ther 2007, 18(June (6)):536-546.
38. Pichlmair A., Diebold S.S., Gschmeissner S., Takeuchi Y., Ikeda Y., Collins M.K., et al. Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J Virol 2007, 81(January (2)):539-547.
39. Schneider J., Gilbert S.C., Hannan C.M., Degano P., Prieur E., Sheu E.G., et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev 1999, 170(August):29-38.